China Historical Balance Sheet

CPHI Stock

USD 0.22 0.01 4.76%

Trend analysis of China Pharma Holdings balance sheet accounts such as Short Long Term Debt Total of 7.4 M, Other Current Liabilities of 1.9 M or Total Current Liabilities of 9.2 M provides information on China Pharma's total assets, liabilities, and equity, which is the actual value of China Pharma Holdings to its prevalent stockholders. By breaking down trends over time using China Pharma balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining China Pharma Holdings latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether China Pharma Holdings is a good buy for the upcoming year.

China Pharma Inventory

3.19 Million

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in China Pharma Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

About China Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of China Pharma Holdings at a specified time, usually calculated after every quarter, six months, or one year. China Pharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of China Pharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which China currently owns. An asset can also be divided into two categories, current and non-current.

China Pharma Balance Sheet Chart

As of now, China Pharma's Property Plant And Equipment Net is decreasing as compared to previous years. The China Pharma's current Net Debt is estimated to increase to about 4.3 M, while Total Assets are projected to decrease to under 18 M.

Short Long Term Debt Total Other Current Liab Total Current Liabilities Net Debt Non Current Assets Total Long Term Debt

Add Fundamental

Total Current Liabilities

Total Current Liabilities is an item on China Pharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of China Pharma Holdings are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Non Current Assets Total

The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.

Long Term Debt

Long-term debt is a debt that China Pharma Holdings has held for over one year. Long-term debt appears on China Pharma Holdings balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on China Pharma Holdings balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Most accounts from China Pharma's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into China Pharma Holdings current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in China Pharma Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	8.8M	4.6M	5.3M	7.4M
Total Assets	17.8M	16.5M	18.9M	18.0M

Short Long Term Debt Total Total Assets

China Pharma balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Current Deferred Revenue	Non Currrent Assets Other	Inventory	Other Current Assets
Total Assets		0.42	0.51	0.68	1.0	0.44	0.2	0.97	0.81	0.73	0.85	0.73	0.89	0.22	0.3	0.38	-0.03	0.64	-0.27	0.93	0.14	0.32	0.93	-0.62	0.92	0.7
Short Long Term Debt Total	0.42		0.03	0.52	0.34	0.9	0.95	0.27	0.37	0.78	0.73	0.78	0.04	0.37	0.48	0.92	0.13	0.93	0.45	0.14	0.55	0.43	0.42	0.32	0.08	0.61
Other Current Liab	0.51	0.03		0.56	0.5	0.33	-0.01	0.47	0.55	0.12	0.48	0.12	0.43	0.41	0.51	0.1	0.09	0.37	-0.42	0.44	-0.14	0.44	0.47	-0.43	0.43	0.06
Total Current Liabilities	0.68	0.52	0.56		0.65	0.48	0.37	0.54	0.68	0.66	0.62	0.66	0.56	0.68	0.85	0.28	0.34	0.74	0.1	0.61	0.67	0.72	0.69	-0.43	0.54	0.35
Total Stockholder Equity	1.0	0.34	0.5	0.65		0.36	0.12	0.98	0.8	0.69	0.8	0.69	0.92	0.17	0.25	0.31	-0.06	0.57	-0.32	0.96	0.09	0.28	0.93	-0.67	0.94	0.68
Property Plant And Equipment Net	0.44	0.9	0.33	0.48	0.36		0.91	0.3	0.44	0.59	0.81	0.59	0.01	0.34	0.45	0.93	0.05	0.91	0.24	0.11	0.26	0.39	0.44	0.32	0.07	0.59
Net Debt	0.2	0.95	-0.01	0.37	0.12	0.91		0.05	0.17	0.54	0.61	0.54	-0.21	0.33	0.44	0.9	0.13	0.83	0.47	-0.11	0.48	0.42	0.25	0.53	-0.16	0.5
Retained Earnings	0.97	0.27	0.47	0.54	0.98	0.3	0.05		0.76	0.63	0.77	0.63	0.92	0.0	0.1	0.27	-0.22	0.48	-0.45	0.94	0.0	0.24	0.9	-0.68	0.95	0.68
Accounts Payable	0.81	0.37	0.55	0.68	0.8	0.44	0.17	0.76		0.65	0.77	0.65	0.65	0.31	0.38	0.37	0.06	0.63	-0.15	0.69	0.09	0.23	0.67	-0.52	0.67	0.48
Cash	0.73	0.78	0.12	0.66	0.69	0.59	0.54	0.63	0.65		0.74	1.0	0.52	0.32	0.41	0.66	0.09	0.82	0.26	0.6	0.5	0.33	0.62	-0.22	0.54	0.62
Non Current Assets Total	0.85	0.73	0.48	0.62	0.8	0.81	0.61	0.77	0.77	0.74		0.74	0.51	0.26	0.36	0.77	-0.02	0.87	-0.08	0.6	0.15	0.38	0.76	-0.2	0.58	0.74
Cash And Short Term Investments	0.73	0.78	0.12	0.66	0.69	0.59	0.54	0.63	0.65	1.0	0.74		0.52	0.32	0.41	0.66	0.09	0.82	0.26	0.6	0.5	0.33	0.62	-0.22	0.54	0.62
Net Receivables	0.89	0.04	0.43	0.56	0.92	0.01	-0.21	0.92	0.65	0.52	0.51	0.52		0.1	0.16	-0.04	-0.06	0.27	-0.41	0.99	0.06	0.2	0.85	-0.83	0.99	0.49
Common Stock Total Equity	0.22	0.37	0.41	0.68	0.17	0.34	0.33	0.0	0.31	0.32	0.26	0.32	0.1		0.9	0.21	0.88	0.52	0.5	0.14	0.5	0.42	0.2	-0.06	0.06	-0.07
Common Stock Shares Outstanding	0.3	0.48	0.51	0.85	0.25	0.45	0.44	0.1	0.38	0.41	0.36	0.41	0.16	0.9		0.26	0.62	0.64	0.39	0.21	0.67	0.72	0.33	-0.1	0.12	0.0
Non Current Liabilities Total	0.38	0.92	0.1	0.28	0.31	0.93	0.9	0.27	0.37	0.66	0.77	0.66	-0.04	0.21	0.26		0.02	0.85	0.33	0.06	0.17	0.2	0.33	0.41	0.02	0.61
Other Stockholder Equity	-0.03	0.13	0.09	0.34	-0.06	0.05	0.13	-0.22	0.06	0.09	-0.02	0.09	-0.06	0.88	0.62	0.02		0.2	0.62	-0.04	0.35	0.1	-0.05	0.04	-0.11	-0.19
Total Liab	0.64	0.93	0.37	0.74	0.57	0.91	0.83	0.48	0.63	0.82	0.87	0.82	0.27	0.52	0.64	0.85	0.2		0.29	0.37	0.49	0.53	0.61	0.05	0.31	0.62
Property Plant And Equipment Gross	-0.27	0.45	-0.42	0.1	-0.32	0.24	0.47	-0.45	-0.15	0.26	-0.08	0.26	-0.41	0.5	0.39	0.33	0.62	0.29		-0.36	0.47	-0.05	-0.28	0.49	-0.44	-0.04
Total Current Assets	0.93	0.14	0.44	0.61	0.96	0.11	-0.11	0.94	0.69	0.6	0.6	0.6	0.99	0.14	0.21	0.06	-0.04	0.37	-0.36		0.11	0.24	0.89	-0.8	0.99	0.55
Short Term Debt	0.14	0.55	-0.14	0.67	0.09	0.26	0.48	0.0	0.09	0.5	0.15	0.5	0.06	0.5	0.67	0.17	0.35	0.49	0.47	0.11		0.64	0.23	0.01	0.04	0.14
Common Stock	0.32	0.43	0.44	0.72	0.28	0.39	0.42	0.24	0.23	0.33	0.38	0.33	0.2	0.42	0.72	0.2	0.1	0.53	-0.05	0.24	0.64		0.42	-0.12	0.19	0.14
Current Deferred Revenue	0.93	0.42	0.47	0.69	0.93	0.44	0.25	0.9	0.67	0.62	0.76	0.62	0.85	0.2	0.33	0.33	-0.05	0.61	-0.28	0.89	0.23	0.42		-0.53	0.86	0.76
Non Currrent Assets Other	-0.62	0.32	-0.43	-0.43	-0.67	0.32	0.53	-0.68	-0.52	-0.22	-0.2	-0.22	-0.83	-0.06	-0.1	0.41	0.04	0.05	0.49	-0.8	0.01	-0.12	-0.53		-0.84	-0.16
Inventory	0.92	0.08	0.43	0.54	0.94	0.07	-0.16	0.95	0.67	0.54	0.58	0.54	0.99	0.06	0.12	0.02	-0.11	0.31	-0.44	0.99	0.04	0.19	0.86	-0.84		0.56
Other Current Assets	0.7	0.61	0.06	0.35	0.68	0.59	0.5	0.68	0.48	0.62	0.74	0.62	0.49	-0.07	0.0	0.61	-0.19	0.62	-0.04	0.55	0.14	0.14	0.76	-0.16	0.56

Click cells to compare fundamentals

China Pharma Account Relationship Matchups

China Pharma balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	21.1M	22.6M	17.8M	16.5M	18.9M	18.0M
Short Long Term Debt Total	7.4M	12.5M	8.8M	4.6M	5.3M	7.4M
Other Current Liab	2.9M	1.3M	1.7M	1.6M	1.8M	1.9M
Total Current Liabilities	11.4M	10.5M	12.7M	6.8M	7.8M	9.2M
Total Stockholder Equity	8.0M	6.0M	4.3M	7.5M	8.6M	8.1M
Property Plant And Equipment Net	15.2M	13.0M	9.6M	6.8M	7.8M	13.2M
Net Debt	6.5M	7.6M	6.7M	3.2M	3.7M	4.3M
Retained Earnings	(28.8M)	(32.2M)	(36.2M)	(39.3M)	(35.4M)	(33.6M)
Accounts Payable	1.2M	926.7K	667.1K	966.4K	1.1M	1.7M
Cash	957.7K	4.9M	2.0M	1.4M	1.6M	2.8M
Non Current Assets Total	15.8M	13.6M	11.8M	10.5M	12.0M	11.4M
Cash And Short Term Investments	957.7K	4.9M	2.0M	1.4M	1.6M	2.8M
Net Receivables	583.3K	835.4K	464.5K	662.4K	596.2K	566.3K
Common Stock Shares Outstanding	4.6M	4.6M	5.3M	3.4M	3.9M	3.8M
Liabilities And Stockholders Equity	21.1M	22.6M	17.8M	16.5M	18.9M	18.0M
Non Current Liabilities Total	1.7M	6.1M	754.7K	2.2M	2.5M	3.5M
Other Stockholder Equity	24.5M	25.6M	28.9M	35.3M	40.6M	20.4M
Total Liab	13.1M	16.6M	13.5M	9.0M	10.4M	12.7M
Property Plant And Equipment Gross	15.2M	41.1M	38.0M	37.2M	42.8M	44.9M
Total Current Assets	5.3M	9.1M	6.0M	6.0M	5.4M	5.1M
Accumulated Other Comprehensive Income	12.3M	12.6M	11.6M	11.5M	13.2M	9.9M
Short Term Debt	6.5M	7.2M	8.8M	3.2M	3.7M	4.4M
Common Stock	45.6K	47.3K	74.9K	10.6K	12.2K	11.6K
Current Deferred Revenue	719.8K	210.0K	520.3K	90.5K	81.5K	77.4K
Non Currrent Assets Other	(15.8M)	(13.6M)	(11.8M)	(397.7K)	(457.3K)	(480.2K)
Inventory	3.7M	3.3M	2.9M	3.7M	3.4M	3.2M
Other Current Assets	75.9K	59.3K	522.3K	178.2K	160.4K	152.3K
Intangible Assets	613.8K	589.6K	2.2M	3.7M	3.3M	3.4M
Other Liab	764.4K	753.4K	805.6K	824.4K	948.1K	718.4K
Property Plant Equipment	19.3M	16.3M	15.6M	13.4M	15.4M	17.9M
Net Tangible Assets	29.9M	9.0M	7.8M	5.9M	5.3M	5.0M
Long Term Debt	2.2M	904.2K	5.3M	1.4M	1.3M	2.5M
Short Term Investments	53.7K	91.4K	13.8K	65.9K	59.3K	80.7K
Short Long Term Debt	6.5M	7.1M	8.7M	3.1M	2.8M	4.3M

Currently Active Assets on Macroaxis

CSX	CSX Corporation
ETON	Eton Pharmaceuticals
ALLT	Allot Communications
DIA	SPDR Dow Jones
SPY	SPDR SP 500

When determining whether China Pharma Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of China Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of China Pharma Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on China Pharma Holdings Stock:

How To Invest In China

Details

Is China Stock a good investment?

Details

What is China Pharma's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China Pharma. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.69)

Revenue Per Share

0.63

Quarterly Revenue Growth

(0.16)

Return On Assets

(0.18)

Return On Equity

(0.75)

The market value of China Pharma Holdings is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China Pharma's value that differs from its market value or its book value, called intrinsic value, which is China Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China Pharma's market value can be influenced by many factors that don't directly affect China Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between China Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if China Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

China Historical Balance Sheet

China Pharma Inventory

3.19 Million

About China Balance Sheet Analysis

China Pharma Balance Sheet Chart

Total Current Liabilities

Net Debt

Non Current Assets Total

Long Term Debt

China Pharma balance sheet Correlations

China Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

China Pharma balance sheet Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 0.99	Net Receivables
Inventory	+ 0.99	Net Receivables
Inventory	+ 0.99	Total Current Assets
Retained Earnings	+ 0.98	Total Stockholder Equity

Inventory	- 0.84	Non Currrent Assets Other
Non Currrent Assets Other	- 0.83	Net Receivables
Non Currrent Assets Other	- 0.8	Total Current Assets
Non Currrent Assets Other	- 0.68	Retained Earnings
Non Currrent Assets Other	- 0.67	Total Stockholder Equity
Non Currrent Assets Other	- 0.62	Total Assets